Phase Ib dose-escalation trial of taselisib (GDC-0032) in combination with HER2-directed therapies in patients with advanced HER2+ breast cancer

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

ESMO Open

Topics

Medicine

Cancer Oncology

Internal Medicine

Molecular Biology

Radiology, Nuclear Medicine And Imaging

Show all topics

DOI

10.1016/j.esmoop.2024.103465

License

CC-BY-NC-ND

Other Formats

PDF